» Articles » PMID: 17096027

Adenoviral-mediated Interferon Alpha Overcomes Resistance to the Interferon Protein in Various Cancer Types and Has Marked Bystander Effects

Overview
Date 2006 Nov 11
PMID 17096027
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously shown that intravesical administration of adenovirus encoding human interferon alpha-2b (Ad-IFN) induced a marked regression of superficial human bladder tumors derived from cells that are resistant to over 1 million units/ml of IFNalpha protein in vitro. In addition, Ad-IFN appeared to produce strong bystander effects. In this study, we show that Ad-IFN causes marked inhibition of cell growth and apoptosis in cells of various tumor types, all of which are resistant to IFNalpha protein. In addition, strong perinuclear IFN staining was seen in all cell lines following Ad-IFN transfection and was never observed after exposure to the IFN protein. Ad-IFN induced proteolytic processing of caspases 3, 8 and 9, indicative of enzymatic activation. However, the caspase-8-selective inhibitor, IETDfmk, blocked apoptosis only in the cell lines that were sensitive to the IFNalpha protein and had minimal effect on Ad-IFN-induced caspase-3 or -9 processing and cell death, indicating that death receptor-independent mechanism(s) were involved in the cytotoxic effects observed for cancer cell lines resistant to the IFNalpha protein. Moreover, we document that a yet to be identified soluble factor(s) is responsible for causing the bystander effect observed following Ad-IFN treatment in IFN protein-resistant cancer cells.

Citing Articles

Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance.

Green J, Osterhout R, Klova A, Merkwirth C, McDonnell S, Zavareh R Mol Ther Oncolytics. 2021; 23:547-559.

PMID: 34938855 PMC: 8645427. DOI: 10.1016/j.omto.2021.11.006.


The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Duplisea J, Mokkapati S, Plote D, Schluns K, McConkey D, Yla-Herttuala S World J Urol. 2018; 37(10):2041-2049.

PMID: 30415317 PMC: 6511323. DOI: 10.1007/s00345-018-2553-7.


Oncolytic viruses: adenoviruses.

Niemann J, Kuhnel F Virus Genes. 2017; 53(5):700-706.

PMID: 28702840 DOI: 10.1007/s11262-017-1488-1.


Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

Benedict W, Fisher M, Zhang X, Yang Z, Munsell M, Dinney C Cancer Gene Ther. 2014; 21(3):91-4.

PMID: 24503570 PMC: 3962717. DOI: 10.1038/cgt.2014.1.


Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Dinney C, Fisher M, Navai N, ODonnell M, Cutler D, Abraham A J Urol. 2013; 190(3):850-6.

PMID: 23507396 PMC: 3951790. DOI: 10.1016/j.juro.2013.03.030.